Finance

Lists
Q2 2026 earnings • released • EPS beat +10.65% • Revenue beat +2.75%
See results
CRL:NYSE
Charles River Lbrtrs ntrntl Inc
$267.49
+0.75%
(+1.98) 1D
$267.49
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
$261.53
High
$267.59
Low
$260.82
Mkt. cap
12.77B
Avg. vol.
948.44K
Volume
612.51K
52-wk high
$268.00
52-wk low
$144.26
EPS
-$4.85
Beta
1.39
Shares outstanding
47.74M
No. of employees
19K
Open
$261.53
High
$267.59
Low
$260.82
Mkt. cap
12.77B
Avg. vol.
948.44K
Volume
612.51K
52-wk high
$268.00
52-wk low
$144.26
EPS
-$4.85
Beta
1.39
Shares outstanding
47.74M
No. of employees
19K
News stories
From sources across the web
Profile
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Lbrtrs ntrntl Inc
CEOJames C. Foster
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 13 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
11
Hold
2
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current $267.49
$310.00 (+15.89%)
Average
$275.64 (+3.05%)
Lowest
$219.00 (-18.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$300.00
+12.2%
08/06/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$291.00
+8.8%
08/06/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
$300.00
+12.2%
08/06/2026
Ryan Halsted
RBC Capital
Buy
Maintained
$282.00
+5.4%
08/05/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
$310.00
+15.9%
08/05/2026
Luke Sergott
Barclays
Buy
Maintained
$300.00
+12.2%
08/05/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$300.00
+12.2%
08/06/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
08/05/2026
Charles Rhyee
TD Cowen
Buy
Maintained
$235.00
-12.1%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
$219.00
-18.1%
07/20/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
$230.00
-14%
07/13/2026
Patrick B Donnelly
Citi
Buy
Maintained
$265.00
-0.9%
07/08/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
-
-
06/05/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
David Windley
Jefferies
Buy
Maintained
$225.00
-15.9%
05/08/2026
Charles Weston
RBC Capital
Buy
Initiated
$215.00
-19.6%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
$175.00
-34.6%
02/25/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$3.02 / $2.73
+10.65%beat
Revenue / Est. (USD)
1.00B / 977.20M
+2.75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.00B
994.23M
995.83M
1.00B
Cost of goods sold
652.72M
665.36M
672.79M
625.06M
Cost of revenue
652.72M
665.36M
672.79M
625.06M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173.64M
192.02M
149.12M
214.18M
Operating expense
201.05M
284.04M
164.46M
227.27M
Total operating expenses
853.77M
949.40M
837.25M
852.33M
Operating income
151.08M
44.83M
158.58M
151.74M
Other non operating income
-22.62M
27.72M
-123.11M
25.99M
EBT including unusual items
87.20M
-294.10M
-29.94M
53.17M
EBT excluding unusual items
104.48M
35.18M
8.62M
148.43M
Income tax expense
31.64M
-17.81M
-15.14M
53.93M
Effective tax rate
36.29%
6.06%
50.56%
101.43%
Other operating expenses
-
-
-
-
Net income
54.42M
-276.56M
-14.84M
-1.48M
Net profit margin
5.42%
-27.82%
-1.49%
-0.15%
Earnings per share
2.43
2.39
2.06
3.02
Interest and investment income
1.42M
1.02M
1.03M
1.03M
Interest expense
-25.40M
-23.78M
-26.74M
-30.34M
Net interest expenses
-23.98M
-22.76M
-25.71M
-29.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
165.25M
169.61M
225.73M
217.54M
Gain or loss from assets sale
-
-
117.98M
24.92M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps